Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France
Over 10 years, the introduction of DOACs in France has generated substantial savings in AF-related costs, highlighting their clinical and economic benefits and the importance for authorities to valorise the external effects of therapeutic innovations.
Authors
- Claire Marant Micallef (ORCID: https://orcid.org/0000-0002-5635-8605)
- R. C. MOREAU
- Nicolas Danchin (ORCID: https://orcid.org/0000-0001-9263-5051)
- D. Guitard-Dehoux
- Manon Belhassen (ORCID: https://orcid.org/0000-0002-9478-5464)
- François-Emery Cotté (ORCID: https://orcid.org/0000-0002-6758-4552)
- Mélanie Nee (ORCID: https://orcid.org/0000-0001-7016-501X)
- C Guilmet
- H. Lesage
Institutions
- Bristol-Myers Squibb (Germany) (DE)
- Bristol-Myers Squibb (France) (FR)
- Hôpital Saint Joseph (FR)
- Hôpital Paris Saint-Joseph (FR)
- National Center of Public Health and Analyses (BG)
- École de management de Lyon (FR)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1080/13696998.2025.2514381
- Citations
- 3
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.16